European Medicines Agency ' s Committee for Medicinal Products for Human Use starts rolling review of molnupiravir for treatment of COVID-19 in adults, EMA

Decision to start rolling review of this oral antiviral medicine is based on preliminary results from lab and clinical studies suggesting it may reduce ability of SARS CoV 2 to multiply in the body, thereby preventing hospitalisation or death in patients with COVID-19.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news